Partially hydrolyzed guar gum in pediatric functional abdominal pain

Table 3 Outcome measures at baseline (T0), at 4 wk of supplementation (T2) and after 8 wk (mean ± SD)

	Group A			Group B
	PHGG 5g/d (n = 30)			Placebo (n = 30)
	Baseline	4 wk (T2)	8 wk (T3)	Baseline	4 wk (T2)	8 wk (T3)
Birmingham Scorea	28.5 ± 7.16	24.3 ± 6.02	23.0 ± 6.15	29.5 ± 6.94	28.4 ± 8.39	28.7 ± 7.54
Bristol Stool Scorea
IBS-c	1.00 ± 1.02	2.02 ± 1.50	2.32 ± 1.50	1.16 ± 0.89	1.76 ± 1.04	1.65 ± 1.08
IBS-d	5.02 ± 0.63	4.01 ± 0.16	4.07 ± 0.12	5.54 ± 0.32	4.86 ± 0.96	4.89 ± 0.73
Wong-Baker Scorea
	2.15 ± 0.14	1.86 ± 0.14	1.63 ± 0.16	2.16 ± 0.17	2.04 ± 0.17	2.05 ± 0.19

^aP < 0.05 vs placebo (Wilcoxon 2-sample test). PHGG: Partially hydrolyzed guar gum; IBS: Irritable bowel syndrome.